SPOTLIGHT -
Acerus Grabs Additional Formulary Status for Testosterone Brand
Coverage now includes 85% of commercial lives.
Acacia Pharma Expects to Meet Formulary Goals
Formulary adoption is a key step in achieving sales pull through starting in 2022, company officials said.
Cigna Moves Remicade Biosimilars to Preferred Formulary Status
Patients are being offered $500 to make the switch.
Biosimilar Insulin Glargine Led to Downward Trend in Pricing
A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.
Study: Medicare Drug Spending Lacks Understanding of Cost-effectiveness
Implementation of value-based approaches requires measurement of value, authors said.
Higher Drug Prices Can Lower Use of Recommended Therapies
Investigators looked at the association of antiparasitic drug prices with prescribing and prescription-filling behaviors and total outpatient treatment costs.
CMS Changes Coverage for CGM Devices
A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.
Consumers Across the Political Spectrum Want Lower Drug Prices, Poll Finds
Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.
Study Indicates Lorbrena not Cost-effective in Untreated NSCLC
Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.
Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
New Dry Eye Therapy Gains Formulary Coverage
Three commercial plans now cover the corticosteroid Eysuvis.
